GB9708265D0 - Contrast agents - Google Patents

Contrast agents

Info

Publication number
GB9708265D0
GB9708265D0 GBGB9708265.5A GB9708265A GB9708265D0 GB 9708265 D0 GB9708265 D0 GB 9708265D0 GB 9708265 A GB9708265 A GB 9708265A GB 9708265 D0 GB9708265 D0 GB 9708265D0
Authority
GB
United Kingdom
Prior art keywords
contrast agent
moiety
image
peptidic
generating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9708265.5A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nycomed Imaging AS filed Critical Nycomed Imaging AS
Priority to GBGB9708265.5A priority Critical patent/GB9708265D0/en
Publication of GB9708265D0 publication Critical patent/GB9708265D0/en
Priority to JP52018698A priority patent/JP2001511765A/en
Priority to PCT/GB1997/002955 priority patent/WO1998018495A2/en
Priority to ES97910514T priority patent/ES2264159T3/en
Priority to JP52018898A priority patent/JP2002515889A/en
Priority to KR1019990703658A priority patent/KR20000052829A/en
Priority to EP97909512A priority patent/EP1007101B1/en
Priority to HU0000357A priority patent/HUP0000357A2/en
Priority to US08/959,206 priority patent/US6331289B1/en
Priority to CN97180164A priority patent/CN1238700A/en
Priority to AT97909512T priority patent/ATE326242T1/en
Priority to PCT/GB1997/002954 priority patent/WO1998018501A2/en
Priority to US08/958,993 priority patent/US6264917B1/en
Priority to DE69735354T priority patent/DE69735354T2/en
Priority to JP10520191A priority patent/JP2001502719A/en
Priority to AU47182/97A priority patent/AU733477B2/en
Priority to CZ991494A priority patent/CZ149499A3/en
Priority to AU47870/97A priority patent/AU4787097A/en
Priority to AU47866/97A priority patent/AU733495B2/en
Priority to IL12944497A priority patent/IL129444A0/en
Priority to BR9712683-7A priority patent/BR9712683A/en
Priority to PCT/GB1997/002953 priority patent/WO1998018500A2/en
Priority to KR1019990703659A priority patent/KR20000052830A/en
Priority to JP52018798A priority patent/JP2001503407A/en
Priority to AU47867/97A priority patent/AU4786797A/en
Priority to EP97910515A priority patent/EP0991427A2/en
Priority to CA002270120A priority patent/CA2270120A1/en
Priority to BR9713978-5A priority patent/BR9713978A/en
Priority to IL12944597A priority patent/IL129445A0/en
Priority to EP97910514A priority patent/EP0973552B1/en
Priority to CA002269985A priority patent/CA2269985A1/en
Priority to AT97910514T priority patent/ATE318618T1/en
Priority to NZ335799A priority patent/NZ335799A/en
Priority to CN97199047A priority patent/CN1234742A/en
Priority to NZ335596A priority patent/NZ335596A/en
Priority to EP97910518A priority patent/EP0963209A2/en
Priority to DE69735901T priority patent/DE69735901T2/en
Priority to PCT/GB1997/002958 priority patent/WO1998018498A2/en
Priority to US08/960,054 priority patent/US6261537B1/en
Priority to DE69837975T priority patent/DE69837975T2/en
Priority to JP54530798A priority patent/JP4993419B2/en
Priority to EP04007226A priority patent/EP1442751B1/en
Priority to PCT/GB1998/001197 priority patent/WO1998047541A1/en
Priority to ES98917461T priority patent/ES2224379T3/en
Priority to AT98917461T priority patent/ATE270116T1/en
Priority to EP98917461A priority patent/EP0977600B1/en
Priority to ES04007226T priority patent/ES2287599T3/en
Priority to DE69824842T priority patent/DE69824842T2/en
Priority to AU70687/98A priority patent/AU7068798A/en
Priority to AT04007226T priority patent/ATE365054T1/en
Priority to DK04007226T priority patent/DK1442751T3/en
Priority to NO991890A priority patent/NO991890L/en
Priority to NO991889A priority patent/NO991889L/en
Priority to BG103439A priority patent/BG103439A/en
Priority to BG103438A priority patent/BG103438A/en
Priority to US09/422,977 priority patent/US6610269B1/en
Priority to US09/765,614 priority patent/US20020102215A1/en
Priority to US09/925,715 priority patent/US6680047B2/en
Priority to CN02160420A priority patent/CN1440816A/en
Priority to US10/462,836 priority patent/US7413727B2/en
Priority to US10/722,075 priority patent/US20040141922A1/en
Priority to US10/734,730 priority patent/US20050002865A1/en
Priority to US11/498,651 priority patent/US20070036722A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1255—Granulates, agglomerates, microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Apparatus For Radiation Diagnosis (AREA)

Abstract

The invention provides a method of generating an image of an animate human or non-human animal subject previously administered with a contrast agent involving generating an image of at least a part of said subject to which said contrast agent has distributed, characterised in that said contrast agent is a composition of matter of formula I V - L - R where V is a vector moiety having affinity for an angiogenesis-related endothelial cell receptor, L is a linker moiety or a bond and R is a detectable moiety, characterised in that V is a non-peptidic organic group, or V is peptidic and R is a macromolecular or particulate species providing a multiplicity of labels detectable in in vivo imaging.
GBGB9708265.5A 1996-10-28 1997-04-24 Contrast agents Pending GB9708265D0 (en)

Priority Applications (63)

Application Number Priority Date Filing Date Title
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents
JP52018698A JP2001511765A (en) 1996-10-28 1997-10-28 Improved diagnostic / therapeutic agents
PCT/GB1997/002955 WO1998018495A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
ES97910514T ES2264159T3 (en) 1996-10-28 1997-10-28 IMPROVEMENTS IN / OR RELATED TO DIAGNOSTIC / THERAPEUTIC AGENTS.
JP52018898A JP2002515889A (en) 1996-10-28 1997-10-28 Improved diagnostic / therapeutic agents
KR1019990703658A KR20000052829A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
EP97909512A EP1007101B1 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
HU0000357A HUP0000357A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
US08/959,206 US6331289B1 (en) 1996-10-28 1997-10-28 Targeted diagnostic/therapeutic agents having more than one different vectors
CN97180164A CN1238700A (en) 1996-10-28 1997-10-28 Improvents in or relating to diagnostic/therapeutic agents
AT97909512T ATE326242T1 (en) 1996-10-28 1997-10-28 IMPROVEMENTS TO OR RELATED TO DIAGNOSTIC/THERAPEUTIC AGENTS
PCT/GB1997/002954 WO1998018501A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
US08/958,993 US6264917B1 (en) 1996-10-28 1997-10-28 Targeted ultrasound contrast agents
DE69735354T DE69735354T2 (en) 1996-10-28 1997-10-28 IMPROVEMENTS AT OR RELATED TO DIAGNOSTIC / THERAPEUTIC COMPOUNDS
JP10520191A JP2001502719A (en) 1996-10-28 1997-10-28 Improved diagnostic / therapeutic agents
AU47182/97A AU733477B2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
CZ991494A CZ149499A3 (en) 1996-10-28 1997-10-28 Diagnostic and/or therapeutic preparation
AU47870/97A AU4787097A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
AU47866/97A AU733495B2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
IL12944497A IL129444A0 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
BR9712683-7A BR9712683A (en) 1996-10-28 1997-10-28 Diagnostic and / or therapeutically active targetable agent, combined formulation, process for preparing and using it, combined formulation, and processes for generating enhanced images of a human or non-human animal body and for in vitro targeting investigation by an agent.
PCT/GB1997/002953 WO1998018500A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
KR1019990703659A KR20000052830A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
JP52018798A JP2001503407A (en) 1996-10-28 1997-10-28 Improved diagnostic / therapeutic agents
AU47867/97A AU4786797A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
EP97910515A EP0991427A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
CA002270120A CA2270120A1 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
BR9713978-5A BR9713978A (en) 1996-10-28 1997-10-28 Targetable and / or therapeutically active diagnostic agent, process for its preparation and use, combined formulation, and processes for generating enhanced images of a human or non-human animal body and for in vitro investigation of targeting by an agent
IL12944597A IL129445A0 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
EP97910514A EP0973552B1 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
CA002269985A CA2269985A1 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
AT97910514T ATE318618T1 (en) 1996-10-28 1997-10-28 IMPROVEMENTS IN OR RELATED TO DIAGNOSTIC/THERAPEUTIC COMPOUNDS
NZ335799A NZ335799A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
CN97199047A CN1234742A (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents and improvement relating to same
NZ335596A NZ335596A (en) 1996-10-28 1997-10-28 Diagnostic and therapeutic agents comprising microbubbles of a reporter, a surfactant and a vector
EP97910518A EP0963209A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
DE69735901T DE69735901T2 (en) 1996-10-28 1997-10-28 ENHANCING OR IN CONNECTION WITH DIAGNOSTIC / THERAPEUTIC AGENTS
PCT/GB1997/002958 WO1998018498A2 (en) 1996-10-28 1997-10-28 Improvements in or relating to diagnostic/therapeutic agents
US08/960,054 US6261537B1 (en) 1996-10-28 1997-10-29 Diagnostic/therapeutic agents having microbubbles coupled to one or more vectors
DE69837975T DE69837975T2 (en) 1997-04-24 1998-04-24 Diagnostic imaging method
JP54530798A JP4993419B2 (en) 1997-04-24 1998-04-24 Contrast agent
EP04007226A EP1442751B1 (en) 1997-04-24 1998-04-24 Diagnostic imaging technique
PCT/GB1998/001197 WO1998047541A1 (en) 1997-04-24 1998-04-24 Contrast agents
ES98917461T ES2224379T3 (en) 1997-04-24 1998-04-24 DIANA CONTRAST AGENTS THAT JOIN RECEIVERS ASSOCIATED WITH ANGIOGENESIS.
AT98917461T ATE270116T1 (en) 1997-04-24 1998-04-24 CONTRAST AGENTS TARGETING ANGIOGENESIS RECEPTORS
EP98917461A EP0977600B1 (en) 1997-04-24 1998-04-24 Contrast agents targetting receptors associated with angiogenesis
ES04007226T ES2287599T3 (en) 1997-04-24 1998-04-24 DIAGNOSTIC IMAGE FORMATION TECHNIQUE.
DE69824842T DE69824842T2 (en) 1997-04-24 1998-04-24 CONTRASTING AGENTS AIMING AT ANGIOGENESIS RECEPTORS
AU70687/98A AU7068798A (en) 1997-04-24 1998-04-24 Contrast agents
AT04007226T ATE365054T1 (en) 1997-04-24 1998-04-24 DIAGNOSTIC IMAGING PROCEDURE
DK04007226T DK1442751T3 (en) 1997-04-24 1998-04-24 Diagnostic Imaging Technique
NO991890A NO991890L (en) 1996-10-28 1999-04-21 Measuring diagnostic and / or therapeutically active agents
NO991889A NO991889L (en) 1996-10-28 1999-04-21 Measuring diagnostic and / or therapeutically active agents
BG103439A BG103439A (en) 1996-10-28 1999-05-27 Therapeutical and diagnostical forms
BG103438A BG103438A (en) 1996-10-28 1999-05-27 Improvements of or in relation to diagnostic/therapeutical forms
US09/422,977 US6610269B1 (en) 1997-04-24 1999-10-22 Contrast agents
US09/765,614 US20020102215A1 (en) 1996-10-28 2001-01-22 Diagnostic/therapeutic agents
US09/925,715 US6680047B2 (en) 1996-10-28 2001-08-10 Diagnostic/therapeutic agents
CN02160420A CN1440816A (en) 1996-10-28 2002-12-30 Improvement for diagnosis and/or therapeutic agnet and its relative improvement
US10/462,836 US7413727B2 (en) 1997-04-24 2003-06-17 Contrast agents
US10/722,075 US20040141922A1 (en) 1996-10-28 2003-11-26 Diagnostic/therapeutic agents
US10/734,730 US20050002865A1 (en) 1996-10-28 2003-12-15 Diagnostic/therapeutic agents
US11/498,651 US20070036722A1 (en) 1996-10-28 2006-08-03 Separation processes

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9708265.5A GB9708265D0 (en) 1997-04-24 1997-04-24 Contrast agents

Publications (1)

Publication Number Publication Date
GB9708265D0 true GB9708265D0 (en) 1997-06-18

Family

ID=10811256

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9708265.5A Pending GB9708265D0 (en) 1996-10-28 1997-04-24 Contrast agents

Country Status (10)

Country Link
US (2) US6610269B1 (en)
EP (2) EP1442751B1 (en)
JP (1) JP4993419B2 (en)
AT (2) ATE365054T1 (en)
AU (1) AU7068798A (en)
DE (2) DE69824842T2 (en)
DK (1) DK1442751T3 (en)
ES (2) ES2287599T3 (en)
GB (1) GB9708265D0 (en)
WO (1) WO1998047541A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988062A1 (en) 1997-05-27 2000-03-29 Mallinckrodt Inc. Selectively binding ultrasound contrast agents

Families Citing this family (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
US6537520B1 (en) 1998-03-31 2003-03-25 Bristol-Myers Squibb Pharma Company Pharmaceuticals for the imaging of angiogenic disorders
CA2324555A1 (en) 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Pharmaceuticals for the imaging of angiogenic disorders
US6548663B1 (en) 1998-03-31 2003-04-15 Bristol-Myers Squibb Pharma Company Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US6524553B2 (en) 1998-03-31 2003-02-25 Bristol-Myers Squibb Pharma Company Quinolone vitronectin receptor antagonist pharmaceuticals
DE19845798A1 (en) * 1998-09-29 2000-04-13 Schering Ag Use of neoangiogenesis markers for diagnosis and therapy of tumors, agents containing them, and methods for their production
US6299860B1 (en) 1998-10-15 2001-10-09 Fluoro Probe, Inc. Method for viewing diseased tissue located within a body cavity
US6284223B1 (en) 1998-10-15 2001-09-04 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6652836B2 (en) 1998-10-15 2003-11-25 Fluoroprobe, Inc. Method for viewing tumor tissue located within a body cavity
US6511649B1 (en) 1998-12-18 2003-01-28 Thomas D. Harris Vitronectin receptor antagonist pharmaceuticals
CN1356913A (en) * 1998-12-18 2002-07-03 杜邦药品公司 Vitronectic receptor antagonist pharmaceuticals
TR200101757T2 (en) 1998-12-18 2001-12-21 Dupont Pharmaceuticais Company Vitronectin receptor antagonist pharmaceuticals
US6794518B1 (en) 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
DE19924138A1 (en) 1999-05-26 2000-11-30 Henkel Kgaa Detachable adhesive connections
GB9922173D0 (en) 1999-09-21 1999-11-17 Zeneca Ltd Chemical compounds
AU785505B2 (en) * 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
DE19951599A1 (en) * 1999-10-27 2001-05-23 Henkel Kgaa Process for adhesive separation of adhesive bonds
WO2001051087A2 (en) * 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6989139B2 (en) * 2000-02-15 2006-01-24 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
DK1272507T3 (en) * 2000-04-12 2005-10-03 Amersham Health As Integrin-binding peptide derivatives
HU230437B1 (en) 2000-06-02 2016-06-28 Board Of Regents, The University Of Texas System Ethylenedicysteine(ec)-drug conjugates, preparations and methods for tissue-specific disease imaging
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
EP1289565B1 (en) 2000-06-02 2015-04-22 Bracco Suisse SA Compounds for targeting endothelial cells
CA2413957A1 (en) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
DE10037884A1 (en) * 2000-08-03 2002-02-21 Henkel Kgaa Accelerated curing process
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
EP2347771A1 (en) 2001-07-10 2011-07-27 Ge Healthcare As Peptide-based compounds for targeted imaging
US7087212B2 (en) * 2001-08-17 2006-08-08 Mallinckrodt, Inc Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
US20030100830A1 (en) * 2001-11-27 2003-05-29 Sheng-Ping Zhong Implantable or insertable medical devices visible under magnetic resonance imaging
US7985402B2 (en) * 2002-03-01 2011-07-26 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
US20050250700A1 (en) * 2002-03-01 2005-11-10 Sato Aaron K KDR and VEGF/KDR binding peptides
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
EP1587944A4 (en) 2002-03-01 2007-03-21 Dyax Corp Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
US7211240B2 (en) * 2002-03-01 2007-05-01 Bracco International B.V. Multivalent constructs for therapeutic and diagnostic applications
EP1369134A1 (en) 2002-06-05 2003-12-10 Bracco Imaging S.p.A. New agents for magnetic imaging method
JP2004138397A (en) * 2002-10-15 2004-05-13 Kyowa Hakko Kogyo Co Ltd Screening method for compound accumulated at specific part
JP5466350B2 (en) 2003-03-03 2014-04-09 ダイアックス、コープ Peptides that specifically bind the HGF receptor (cMet) and uses thereof
JP2007521254A (en) * 2003-06-25 2007-08-02 ゲルベ Diagnostic imaging compounds
FR2856689A1 (en) * 2003-06-25 2004-12-31 Guerbet Sa New targeted diagnostic agents, used especially for detecting cardiovascular, cancerous or inflammatory disorders, comprise high relaxivity signal moiety bonded via linker to biovector
NO20034350D0 (en) * 2003-09-29 2003-09-29 Amersham Health As Optical imaging of colorectal cancer
US7431915B2 (en) 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
NO20035681D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of lung cancer
NO20035683D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of prostate cancer
NO20035682D0 (en) * 2003-12-18 2003-12-18 Amersham Health As Optical imaging of oesophageal cancer and Barrett's oesophagus
NO20035748D0 (en) * 2003-12-19 2003-12-19 Amersham Health As Optical imaging of vulnerable arteriosclerosis
US20070098631A2 (en) * 2004-04-28 2007-05-03 Guerbet Diagnostic compounds comprising a scaffold coupled to a signal entity for medical imaging diagnostic
US7553810B2 (en) * 2004-06-16 2009-06-30 Pneumrx, Inc. Lung volume reduction using glue composition
US20050281798A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting sites of damaged lung tissue using composition
US20050281740A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue
US20050281739A1 (en) * 2004-06-16 2005-12-22 Glen Gong Imaging damaged lung tissue using compositions
US7608579B2 (en) * 2004-06-16 2009-10-27 Pneumrx, Inc. Lung volume reduction using glue compositions
US20050281799A1 (en) * 2004-06-16 2005-12-22 Glen Gong Targeting damaged lung tissue using compositions
US7678767B2 (en) 2004-06-16 2010-03-16 Pneumrx, Inc. Glue compositions for lung volume reduction
JP5113519B2 (en) * 2004-07-08 2013-01-09 ヌームアールエックス・インコーポレーテッド Treatment device, treatment method and material for pleural effusion
EP1619501B1 (en) * 2004-07-22 2007-09-26 Bayer Schering Pharma Aktiengesellschaft Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
GB0421308D0 (en) * 2004-09-24 2004-10-27 Amersham Plc Enzyme inhibitor imaging agents
CN101203249A (en) * 2005-04-01 2008-06-18 德克萨斯大学体系董事会 Poly(peptide) as a chelator: methods of manufacture and uses
CA2606270A1 (en) * 2005-04-19 2006-10-26 Massachusetts Institute Of Technology Amphiphilic polymers and methods of use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
US8815804B2 (en) * 2006-02-06 2014-08-26 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting tumors and wounds
US8758723B2 (en) * 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
EP2064300A4 (en) * 2006-09-20 2013-05-22 Pneumrx Inc Tissue adhesive compositions and methods thereof
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US8188220B2 (en) 2006-12-06 2012-05-29 Sanford-Burnham Medical Research Institute Methods and compositions related to targeting wounds, regenerating tissue, and tumors
EP2117575A4 (en) 2007-01-03 2013-06-05 Burnham Inst Medical Research Methods and compositions related to clot binding compounds
DE102007036570A1 (en) 2007-08-03 2009-02-19 Siemens Ag Screening test for detection of prostate disease and device and diagnostic substance for performing the test
DE102007037008B4 (en) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnostic substance for use in a method for determining the aggressiveness of a prostate tumor
DE102007041836A1 (en) * 2007-09-03 2009-03-05 Siemens Ag Method of imaging a prostate tumor and contrast agent
US20090074672A1 (en) * 2007-09-17 2009-03-19 Sri International Tumor Boundary Imaging
WO2009039207A1 (en) 2007-09-19 2009-03-26 Oncofluor, Inc. Method for imaging and treating organs and tissues
US20100143258A1 (en) * 2008-12-05 2010-06-10 General Electric Company Tumor margin imaging agents
WO2010075540A1 (en) * 2008-12-23 2010-07-01 Burnham Institute For Medical Research Methods and compositions for synaphically-targeted treatment for cancer
JP2012513589A (en) 2008-12-23 2012-06-14 ジーイー・ヘルスケア・リミテッド Application of 99mTc-peptide compounds as bone marrow imaging agents
US11235062B2 (en) * 2009-03-06 2022-02-01 Metaqor Llc Dynamic bio-nanoparticle elements
US11096901B2 (en) 2009-03-06 2021-08-24 Metaqor Llc Dynamic bio-nanoparticle platforms
US9808532B2 (en) 2009-07-15 2017-11-07 The Regents Of The University Of California Peptides whose uptake in cells is controllable
CA2775747A1 (en) 2009-10-07 2011-04-14 Sanford Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
WO2011049964A1 (en) 2009-10-19 2011-04-28 Lab Scientific Group Rna detection and quantitation
US8912136B2 (en) 2009-12-18 2014-12-16 Sanford-Burnham Medical Research Institute Methods and compositions related to clot-binding compounds
JP6184101B2 (en) 2009-12-23 2017-08-23 サンフォード−バーナム メディカル リサーチ インスティテュート Methods and compositions for annexin 1 binding compounds
WO2011127405A1 (en) 2010-04-08 2011-10-13 Sanford-Burnham Medical Research Institute Methods and compositions for enhanced delivery of compounds
WO2012136813A2 (en) 2011-04-07 2012-10-11 Universitetet I Oslo Agents for medical radar diagnosis
WO2012170356A1 (en) 2011-06-04 2012-12-13 Rochester General Hospital Research Institute Compositions and methods related to p6 of haemophilus influenzae
US20140308342A1 (en) 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
WO2014120837A2 (en) 2013-01-29 2014-08-07 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellulary releaseable prodrug
WO2014120974A1 (en) 2013-01-30 2014-08-07 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
DK3193945T3 (en) * 2014-09-17 2020-11-16 Fluoguide As UPAR TARGETED PEPTIME FOR USE IN PEROPERATIVE OPTICAL IMAGING OF INVASIVE CANCER
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
EP3037820A1 (en) * 2014-12-27 2016-06-29 Miltenyi Biotec GmbH Cell detection methods and reagents having a releasable labelling moiety
WO2016149363A1 (en) * 2015-03-16 2016-09-22 Northwestern University Contrast-agent-labeled peptide amphiphile nanofibers
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
KR20180112060A (en) 2016-02-23 2018-10-11 타베다 세라퓨틱스, 인코포레이티드 HSP90 targeted conjugates and their particles and formulations
EP3490615A4 (en) * 2016-07-27 2020-04-01 The Trustees of Columbia University in the City of New York Gel-bound compositions for radiotherapy and uses thereof
EP3412303A1 (en) 2017-06-08 2018-12-12 Medizinische Universität Innsbruck Improved pharmacokinetics and cholecystokinin-2 receptor (cck2r) targeting for diagnosis and therapy
JP2022521353A (en) 2019-03-22 2022-04-06 リフレクション ファーマシューティカルズ， インコーポレイテッド D-Peptidic Compounds for VEGF

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672334A (en) * 1991-01-16 1997-09-30 Access Pharmaceuticals, Inc. Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
EP0436005B1 (en) * 1989-07-20 1995-03-29 Sandoz Ltd. Labeled polypeptide derivatives
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US6107459A (en) * 1991-02-08 2000-08-22 Diatide, Inc. Technetium-99m labeled peptides for diagnostic imaging
PT627940E (en) 1992-03-05 2003-07-31 Univ Texas USE OF IMMUNOCONJUGATES FOR THE DIAGNOSIS AND / OR THERAPY OF VASCULARIZED TUMORS
US5508020A (en) * 1992-06-05 1996-04-16 Diatech, Inc. Technetium-99M labeled peptides for imaging
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
CN1701814A (en) * 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 F1K-1 is a receptor for vascular endothelial growth factor
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
JP3670309B2 (en) * 1993-04-01 2005-07-13 第一製薬株式会社 Bicyclic heterocyclic compounds
US5480970A (en) 1993-12-22 1996-01-02 Resolution Pharmaceuticals Metal chelators
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
GB9502065D0 (en) * 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
US6027711A (en) * 1995-06-07 2000-02-22 Rhomed Incorporated Structurally determined metallo-constructs and applications
DE19522774A1 (en) * 1995-06-27 1997-01-02 Ifu Gmbh Appliance for spectroscopic examination of specimens taken from human body
CA2242425C (en) * 1996-02-13 2006-07-18 Zeneca Limited Quinazoline derivatives as vegf inhibitors
EP1683520B1 (en) * 1996-03-12 2013-11-20 PG-TXL Company, L.P. Water-soluble prodrugs
DE69716900T2 (en) * 1996-04-10 2003-07-03 Merck & Co., Inc. Alpha v Beta 3 ANTAGONISTS
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
GB9708265D0 (en) * 1997-04-24 1997-06-18 Nycomed Imaging As Contrast agents
EP0975792B1 (en) * 1997-03-04 2007-10-10 Savient Pharmaceuticals, Inc. Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
WO1999040947A2 (en) 1998-02-11 1999-08-19 Resolution Pharmaceuticals Inc. Angiogenesis targeting molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0988062A1 (en) 1997-05-27 2000-03-29 Mallinckrodt Inc. Selectively binding ultrasound contrast agents

Also Published As

Publication number Publication date
WO1998047541A1 (en) 1998-10-29
ES2287599T3 (en) 2007-12-16
US20040009122A1 (en) 2004-01-15
JP4993419B2 (en) 2012-08-08
US7413727B2 (en) 2008-08-19
ATE270116T1 (en) 2004-07-15
US6610269B1 (en) 2003-08-26
DE69837975D1 (en) 2007-08-02
ATE365054T1 (en) 2007-07-15
DE69837975T2 (en) 2008-02-28
EP1442751A1 (en) 2004-08-04
ES2224379T3 (en) 2005-03-01
JP2002511845A (en) 2002-04-16
AU7068798A (en) 1998-11-13
EP0977600A2 (en) 2000-02-09
DE69824842T2 (en) 2005-11-17
DE69824842D1 (en) 2004-08-05
EP1442751B1 (en) 2007-06-20
EP0977600B1 (en) 2004-06-30
DK1442751T3 (en) 2007-09-24

Similar Documents

Publication Publication Date Title
GB9708265D0 (en) Contrast agents
ATE314097T1 (en) CONTRAST AGENTS
WO1998018497A3 (en) Contrast agents
CY1119742T1 (en) BIOLOGICAL INTERFERENCE-INGREDIENT TRANSPORT SYSTEMS
IT1270882B (en) FUNGICIDE-BASED OLIGOPEPTIDES
DE69331319D1 (en) Biotin-DOTA conjugates and their use in "pretargeting" processes
DE69619526D1 (en) FGF9 AS A SPECIFIC LIGAND FOR FGFR3
DK0640622T3 (en) Polysaccharide derivative and drug carrier
EP1199360A3 (en) Active and inactive CC-chemokine receptors and nucleic acid molecules encoding said receptor
DK0907379T3 (en) Bioactivated diagnostic imaging contrast agent
PT1181319E (en) Chimeric dr4 antibodies and uses thereof
IT1240336B (en) PHARMACEUTICAL, DIETETIC OR VETERINARY COMPOSITIONS FOR EUMETABOLIC ACTIVITIES
ATE228780T1 (en) FATTY ACIDS AS A NUTRITIONAL SUPPLEMENT
EP1086622A3 (en) A construction for automatically milking animals
DE69819685D1 (en) LINING MISCHANLAGE
EA200000198A1 (en) 2-ACYLAMINOPROPANAMINES AS ANTAGONISTS OF TACHYKININ RECEPTORS
ATE425770T1 (en) CONTRAST AGENTS
OA09745A (en) "Anti-oncostatin M mococlonal antibodies".
MA25414A1 (en) CARBOXYLIC ACID AMIDES OF PHENYLCYCLOHEXANE WHICH HAVE AN INHIBITORING EFFECT OF ADENOSINE BINDING.
ATE136512T1 (en) IMPROVEMENTS TO BIKE HANGER DRAWBARS
FR2771051B3 (en) TRAILER HITCHING DEVICE
IT232654Y1 (en) TRAILER FOR HORSE AND SIMILAR TRANSPORT.
ES2153710T3 (en) COLLAR BARRIER INCLUDING ANTI-STEPS.
RU96110020A (en) METHOD FOR ANIMAL GENETIC IDENTIFICATION
ITVI930179A0 (en) IMPROVED TYPE TENDON BOOTS FOR HORSES